| Company Name: |
DC Chemicals Gold |
| Tel: |
021-58447131 13564518121 |
| Email: |
doncunbiosci@gmail.com |
1H-Pyridazino[4,5-e][1,3,4]thiadiazin-5(6H)-one, 3-[[(2,4-dichlorophenyl)methyl]thio]-1,6-dimethyl- manufacturers
- BTB09089
-
- $65.00
-
2026-06-02
- CAS:245728-44-3
- Purity: 99.78%
- Supply Ability: 10g
|
| | 1H-Pyridazino[4,5-e][1,3,4]thiadiazin-5(6H)-one, 3-[[(2,4-dichlorophenyl)methyl]thio]-1,6-dimethyl- Basic information |
| Product Name: | 1H-Pyridazino[4,5-e][1,3,4]thiadiazin-5(6H)-one, 3-[[(2,4-dichlorophenyl)methyl]thio]-1,6-dimethyl- | | Synonyms: | 1H-Pyridazino[4,5-e][1,3,4]thiadiazin-5(6H)-one, 3-[[(2,4-dichlorophenyl)methyl]thio]-1,6-dimethyl-;GPR65 agonist (BTB09089);BTB09089;BTB09089, 10 mM in DMSO;GPR65 agonist | | CAS: | 245728-44-3 | | MF: | C14H12Cl2N4OS2 | | MW: | 387.31 | | EINECS: | | | Product Categories: | | | Mol File: | 245728-44-3.mol | ![1H-Pyridazino[4,5-e][1,3,4]thiadiazin-5(6H)-one, 3-[[(2,4-dichlorophenyl)methyl]thio]-1,6-dimethyl- Structure](CAS/20210111/GIF/245728-44-3.gif) |
| | 1H-Pyridazino[4,5-e][1,3,4]thiadiazin-5(6H)-one, 3-[[(2,4-dichlorophenyl)methyl]thio]-1,6-dimethyl- Chemical Properties |
| Boiling point | 500.6±60.0 °C(Predicted) | | density | 1.57±0.1 g/cm3(Predicted) | | pka | -0.51±0.40(Predicted) | | form | Solid | | color | Yellow to orange | | InChI | InChI=1S/C14H12Cl2N4OS2/c1-19-11-6-17-20(2)13(21)12(11)23-14(18-19)22-7-8-3-4-9(15)5-10(8)16/h3-6H,7H2,1-2H3 | | InChIKey | PIAWQVCBQLTEIY-UHFFFAOYSA-N | | SMILES | S1C2C(=O)N(C)N=CC=2N(C)N=C1SCC1=CC=C(Cl)C=C1Cl |
| | 1H-Pyridazino[4,5-e][1,3,4]thiadiazin-5(6H)-one, 3-[[(2,4-dichlorophenyl)methyl]thio]-1,6-dimethyl- Usage And Synthesis |
| Uses | BTB09089 is a T cell death-associated gene 8 (TDAG8/GPR65) specific agonist. BTB09089 increases TDAG8 expression and regulates the cytokine production of T cells and macrophages[1]. | | in vivo | BTB09089 (5-20 μM, 8 μL; i.c.v.; 6 hours prior to MCAO) reduces cerebral ischaemia-reperfusion injury in rats[2]. | Animal Model: | Adult male SD rats (270-280 g), middle cerebral artery occlusion (MCAO) model[2] | | Dosage: | 5, 10 and 20 μM, 8 μL | | Administration: | Intracerebroventricular injection, six hours prior to MCAO | | Result: | Up-regulated TDAG8 and Bcl-2 expression and down-regulated cleaved caspase-3 expression, while the infarction volume was reduced, and neurological deficits were ameliorated 24 and 72 h after MCAO. |
| | References | [1] Onozawa Y, et al. Activation of T cell death-associated gene 8 regulates the cytokine production of T cells and macrophages in vitro. Eur J Pharmacol. 2012 May 15;683(1-3):325-31. DOI:10.1016/j.ejphar.2012.03.007 [2] Ma XD, et al. TDAG8 activation attenuates cerebral ischaemia-reperfusion injury via Akt signalling in rats. Exp Neurol. 2017 Jul;293:115-123. DOI:10.1016/j.expneurol.2017.03.023 |
| | 1H-Pyridazino[4,5-e][1,3,4]thiadiazin-5(6H)-one, 3-[[(2,4-dichlorophenyl)methyl]thio]-1,6-dimethyl- Preparation Products And Raw materials |
|